ONCOCLINICAS (ONCO3) Main Indicators
Basic Data - ONCO3
| Company | ONCOCLINICAS |
| Corporate Name | ONCOCLINICAS DO BRASIL SERVICOS MEDICOS S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Exploração de serviços médicos. participação em outras sociedades. nacionais ou estrangeiras. pesquisa e desenvolvimento experimental em ciências físicas e naturais. intermediação em pesquisa clínica. |
| Share | ONCO3 |
| Quote Date | 04/01/2025 |
| Share Type | ON |
| Last Closing | R$ 5.69 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 22.72 M |
| Last Statement | DFP - 12/31/2024 |
| Sector | Saúde |
| Subsector | Serv.Méd.Hospit..Análises e Diagnósticos |
| Segment | Serv.Méd.Hospit..Análises e Diagnósticos |
| Participation Indexes | GPTW, IBRA, IBRX, ICON, IGC, IGCT, IGNM, ITAG, SMLL |
| Updated 04/02/2025 | |
Relative Prices - ONCO3
| Price/Earnings | -5.74 |
| Price/SBV | 1.18 |
| Price/Net Sales | 0.60 |
| Price/CFO | -20.06 |
| Price/FCF | -9.29 |
| Price/Total Assets | 0.33 |
| Price/EBIT | -30.92 |
| Price/Working Capital | 1.68 |
| Price/NCAV | -0.63 |
| EV/EBIT | -72.00 |
| EV/EBITDA | 41.84 |
| EV/Net Sales | 1.39 |
| EV/CFO | -46.72 |
| EV/FCF | -21.64 |
| EV/Total Assets | 0.77 |
| Company Market Cap | R$ 3.71 B |
| Enterprise Value | R$ 8.64 B |
| Current Financial Statement Date | 12/31/2024 |
| Current Share Price | R$ 5.69 |
| Share Price Date | 04/01/2025 |
| Dividend Yield | 0.00% |
| Updated 04/02/2025 | |
Income Statement - ONCO3
| Net Revenue | R$ 6.23 B |
| Gross Result | R$ 2.06 B |
| EBIT | - R$ 119.95 M |
| Depreciation and Amortization | - R$ 326.38 M |
| EBITDA | R$ 206.43 M |
| Net Profit | - R$ 646.19 M |
| Net Profit/Share | - R$ 0.99 |
| Updated 03/28/2025 | |
| Net Revenue | R$ 1.57 B |
| Gross Result | R$ 503.08 M |
| EBIT | - R$ 692.81 M |
| Depreciation and Amortization | - R$ 116.92 M |
| EBITDA | - R$ 575.90 M |
| Net Profit | - R$ 643.14 M |
| Profit/Share | - R$ 0.99 |
| Updated 03/28/2025 | |
Price and Volume Behavior - ONCO3
| Lowest Price 52 weeks | R$ 1.77 |
| Highest Price 52 weeks | R$ 9.38 |
| Variation 2025 | 140.08% |
| Variation 1 year | -33.22% |
| Variation 2 years(total) | -30.01% |
| Variation 2 years(yearly) | -16.30% |
| Variation 3 years(total) | -47.31% |
| Variation 3 years(yearly) | -19.22% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 30.94 M |
| Updated 04/02/2025 | |
Returns and Margins - ONCO3
| Return on Initial Tangible Capital | -2.56% |
| Return on Initial Invested Capital | -1.26% |
| Pre-Tax Return on Initial Tangible Capital | -3.87% |
| Pre-Tax Return on Initial Invested Capital | -1.90% |
| Return on Initial Shareholder´s Equity | -28.08% |
| Return on Initial Asset | -7.04% |
| Gross Margin | 33.09% |
| Net Margin | -10.38% |
| EBIT Margin | -1.93% |
| EBITDA Margin | 3.31% |
| Initial Asset Turnover | 0.68 |
| Financial Leverage | 3.56 |
| Liabilities/Net Worth | 2.56 |
| Net Debt/EBITDA | 23.87 |
| Updated 03/28/2025 | |
Balance Sheet - ONCO3
| Cash and Cash Equivalents | R$ 550.74 M |
| Total Assets | R$ 11.20 B |
| Short-Term Debt | R$ 813.96 M |
| Long-Term Debt | R$ 4.66 B |
| Gross Debt | R$ 5.48 B |
| Net Debt | R$ 4.93 B |
| Shareholder´s Equity | R$ 3.15 B |
| Share Book Value | R$ 4.83 |
| Common Shares | 651,756,313 |
| Preferred Shares | 0 |
| Total | 651,756,313 |
| Common Shares in Treasury | 18,963,632 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 18,963,632 |
| Common Shares (Except Treasury) | 632,792,681 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 632,792,681 |
| Updated 03/28/2025 | |
Cash Flow - ONCO3
| Operating Cash Flow | - R$ 184.85 M |
| Cash Flow from Investments | - R$ 1.72 B |
| Financing Cash Flow | R$ 1.91 B |
| Increase (Reduction) in Cash and Equivalents | R$ 40.00 thousand |
| Updated 03/28/2025 | |
| Operating Cash Flow | R$ 32.44 M |
| Cash Flow from Investments | R$ 156.18 M |
| Financing Cash Flow | - R$ 259.50 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 70.66 M |
| Updated 03/28/2025 | |
Experimental - ONCO3
| CAPEX 3 months | - R$ 32.83 M |
| Free Cash Flow 3 months | - R$ 394.00 thousand |
| CAPEX 12 months | - R$ 214.25 M |
| Free Cash Flow 12 months | - R$ 399.10 M |
| Updated 03/28/2025 | |